|
馆藏外文新刊题录
No. 1 January 15, 2010
1. The Janus-faced role of ezrin in “linking”cells to either normal or metastatic phenotype.
Daria Brambilla, et al International Journal of Cancer 2009 125(10):2239
2. Detection of epidermal growth factor receptor mutations in plasma in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
Chen He, et al International Journal of Cancer 2009 125(10):2393
3. Characteristics of menstruation and pregnancy and the risk of lung cancer in women.
Anita Koushik, et al International Journal of Cancer 2009 125(10):2428
4. EGFR and KRAS status of primary sarcimatoid carcinomas of the lung: Impications for anti-EGFR treatment of a rare lung malignancy
Antoine Italiano, et al International Journal of Cancer 2009 125(10):2479
5. Overexpression of Sp1 leads to p53-dependent apoptosis in cancer cells.
Jian-Ying Chuang, et al International Journal of Cancer 2009 125(9):2066
6. Epidemiologic evaluation of pharmaceuticals with limited evidence of carcinogenicity.
Gary D. Friedman, et al International Journal of Cancer 2009 125(9):2173
7. Gene transfer of NK4, an angiogenesis inhibitor, induces CT26 Tumor regression via tumorspecific T lympyocyte activation.
Takeshi Kubota, et al International Journal of Cancer 2009 125(12):2879
8. TP53 Arg72Pro polymorphism and lung cancer risk: A meta-analysis.
Lili Yan, et al International Journal of Cancer 2009 125(12):2903
9. Facts and Fiction of the relationship between preexisting tuberculosis and lung cancer risk: A systematic review.
Hui-Ying Liang, et al International Journal of Cancer 2009 125(12):2936
10. Pattern of Antioxidant and DNA Repair Gene Expression in Normal Airway Epithelium Associated with lung Cancer Diagnosis.
Thomas Blomquist, et al. Cancer Research 2009 69 (22):8629
11. The Fibroblast Growth Factor Receptor Inhibitor PD173074 Blocks Small Cell Lung Cancer Growth in vitro and in vivo.
Olivier E. Pardo, et al. Cancer Research 2009 69 (22):8645
12. Paradoxical Dependencies of Tumor Dormancy and Progression on Basic Cell Kinetics.
Heiko Enderling, et al. Cancer Research 2009 69 (22):8814
13. Snail Promotes CXCR2 Ligand-Dependent Tumor Progression in Non-Small Cell Lung Carcinoma.
Jane Yanagawa, et al. Clinical Cancer Research 2009 15(22):6820
14. Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer.
Lauren Averett Byers, et al. Clinical Cancer Research 2009 15(22):6852
15. Circulating Tumor Cell as a Diagnostic Marker in Primary Lung Cancer.
Fumihiro Tanaka, et al. Clinical Cancer Research 2009 15(22):6980
16. Pemetrexed in the treatment of advanced non-squamous lung cancer.
A.Rossi, et al. Lung Cancer 2009 66 (2):141
17. Genetic variation in telomere maintenance genes, telomere length, and lung cancer susceptibility.
H.D. Hosgood III, et al. Lung Cancer 2009 66 (2):157
18. Pyrogallol induces G2-M arrest in human lung cells and inhibits tumor growth in an animal model.
C.-J. Yang, et al. Lung Cancer 2009 66 (2):162
19.MiR-126 restoration dow3n-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo.
B. Liu, et al. Lung Cancer 2009 66 (2):169
20. Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer.
T.Gu, et al. Lung Cancer 2009 66 (2):176
21. Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleual mesothelioma(MPM) cells.
S. Amatori, et al. Lung Cancer 2009 66 (2):184
22. Comparison of EUS-guided fine needle aspiration and integrated PET-CT in restagung after treatment for locally advanced non-small cell lung cancer.
J.A.Stigt, et al. Lung Cancer 2009 66 (2):198
23. Clinical usefulness of the fluorodeoxylucose(FDG)-PET maximal standardized uptake value (SUV) in combination with CT features for the differentiation of adenocarcinoma with a bronchioloalveolar carcinoma from other subtypes of non-small cell lung cancers.
J.S.Sun, et al. Lung Cancer 2009 66 (2):205
24. Doubling time of lung cancer determined using three-dimensional volumetric software: Comparison of squamous cell carcinoma and adenocarcinoma.
O.Honda, et al. Lung Cancer 2009 66 (2):211
25.Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer.
K.Zarogoulidis, et al. Lung Cancer 2009 66 (2):226
26. Approaches to developing new drugs against tuberculosis
Patrick J.brennan Tuberculosis 2009 89 (5):329
27. Discovery and validation of new antitubercular compounds as potential drug leads and probes.
Robert C.Goldman, et al. Tuberculosis 2009 89 (5):331
28. High-throughput screening for inhibitors of Mycobacterium tuberculosis H#&Rv.
Subramaniam Ananthan, et al. Tuberculosis 2009 89 (5):334
29. Antituberculosis activity of the molecular libraries screening center network library.
Joseph A.Maddry, et al. Tuberculosis 2009 89 (5):354
30. New anti-tuberculosis agents amongst known drugs.
Kathryn E.A. Lougheed, et al. Tuberculosis 2009 89 (5):364
31. Dry-powder pulmonary insufflation in the mouse for application to vaccine or drug studies.
Melissa Morello, et al. Tuberculosis 2009 89 (5):371
32. A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria.
Nageshwar R..Budha, et al. Tuberculosis 2009 89 (5):378
33.Tbrowse: An integrative genomics map of Mycobacterium tuberculosis.
Anshu Bhardwaj, et al. Tuberculosis 2009 89 (5):386
34. Prurigo nodularis due to Mycobacterium tuberculosis.
L.Saporito, Journal of Medical Microbiology 2009 58(12):1649
35.Genetic Abnormalities of the EGFR Pathway in African American patients with Non-Small Cell Lung Cancer.
Rom S. Leidner, et al. Journal of Clinical Oncology 2009 27(33):5620
36. Randomized Phase III Trial of Gemcitabine-Based Chemotherapy with in Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non-Small-Cell Lung Cancer.
Craig Reynolds, et al. Journal of Clinical Oncology 2009 27(34):5808
37. Quality of Life Supersedes the Classic Prognosticators for Lung-Term Survival in Locally Advanced Non-Small-Cell Lung Cancer: An Analysis of RTOG 9801.
Benjamin Movsas, et al. Journal of Clinical Oncology 2009 27(34):5816
38. Polymorphisms in the CASPASE Genes and Survival in Patients With Early-Stage Non-Small-Cell Lung Cancer.
Seung Soo Yoo, et al. Journal of Clinical Oncology 2009 27(34):5823
39. The 3rd International Cancer Control Congress: International collaboration in an era of cancer as a global concern..
Marco A Pierotti, et al. Tumori 2009 95(5):565
40. Cancer control-planning and monitoring population-based systems.
Joe B Harford, et al. Tumori 2009 95(5):568
41. International collaborations in cancer control and the Third International Cancer Control Congress.
Andrea Micheli, et al. Tumori 2009 95(5):579
42. Cancer prevention and population-based screening.
Silvana Luciani, et al. Tumori 2009 95(5):597
43. Comprehensive cancer control-research &development: knowing what we do and doing what we know.
Jon F Kerner, et al. Tumori 2009 95(5):610
44. Critical factors influencing the establishment, maintenance and sustainability of population - based cancer control programs.
Edward J Trapido, et al. Tumori 2009 95(5):637
45. Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells.
Hiromi Hanaka, et al. Tumori 2009 95(5):18757
46. Targeted Drug and Gene Delivery Systems for Lung Cancer Therapy.
Ruchit Trivedi, et al. Clinical Cancer Research 2009 15(23):7299
47. A Four-Gene Signature from NCI-60 Cell Line for Survival Prediction in Non-Small Cell Lung Cancer.
Yi-Chiung Hsu, et al. Clinical Cancer Research 2009 15(23):7309
48. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
Yasuhiro Goto, et al. Cancer Research 2009 69(23):9073
49. Biomarkers of infection for the differential diagnosis of pleural effusions.
J.M.Porcel, et al. European Respiratory Journal 2009 34(6):1383 |
